Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Xencor, Inc. develops antibody and protein therapeutics to treat cancer and autoimmune inflammation. The Company markets its products to healthcare providers and facilities worldwide.
Website: xencor.com


  • Bad financial results growth rate -40.7% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (5.5%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -18.5% (LTM)
  • Share price is 86.0% higher than minimum and 60.7% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (500.0x vs 30.0x)
  • For the last 3 months insiders sold company shares on $3.0 mln (-0.328% of cap.)

Key Financials (Download financials)

Ticker: XNCR
Share price, USD:  (0.0%)13.02
year average price 11.49  


year start price 15.06 2025-02-24

min close price 7.00 2025-08-11

max close price 18.14 2025-12-04

current price 13.02 2026-02-23
Common stocks: 57 212 737

Dividend Yield:  0.0%
EV / Sales: 9.3x
Margin (EBITDA LTM / Revenue): -220.9%

Target EV / EBITDA (hist percentile): 30.0x
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 745
Net Debt ($m): 58
EV (Enterprise Value): 803
EBITDA LTM (млн $): -190
Price to Book: 1.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-01-01seekingalpha.com

Xencor: Fortress Balance Sheet Bodes Well For XmAb819 And XmAb942

2025-11-05zacks.com

Xencor (XNCR) Reports Q3 Loss, Misses Revenue Estimates

2025-10-24seekingalpha.com

Xencor, Inc. (XNCR) Discusses Initial Phase I Dose Escalation Results for XmAb819 in Advanced Clear Cell Renal Cell Carcinoma Transcript

2025-09-19seekingalpha.com

Xencor: Bispecific Antibody Program Takes Shape With Q4 Data Release

2025-09-18zacks.com

Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength?

2025-02-27zacks.com

Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates

2025-01-21zacks.com

Down -21.69% in 4 Weeks, Here's Why Xencor (XNCR) Looks Ripe for a Turnaround

2025-01-20zacks.com

After Plunging -20.27% in 4 Weeks, Here's Why the Trend Might Reverse for Xencor (XNCR)

2025-01-15zacks.com

Here's Why Xencor (XNCR) is Poised for a Turnaround After Losing -23.68% in 4 Weeks

2025-01-14zacks.com

Xencor (XNCR) Upgraded to Strong Buy: Here's What You Should Know
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol XNCR XNCR XNCR XNCR XNCR XNCR XNCR XNCR XNCR XNCR XNCR XNCR XNCR XNCR
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-05 2025-08-06 2024-11-06 2024-08-05 2024-05-09 2023-11-08 2023-08-03 2023-05-08 2022-11-07
acceptedDate 2025-11-05 16:03:34 2025-08-06 16:02:58 2025-02-27 08:05:38 2024-11-06 16:09:09 2024-08-05 16:12:39 2024-05-09 16:02:08 2025-02-24 08:02:42 2023-11-07 18:00:25 2023-08-03 17:28:45 2023-05-08 17:15:39 2023-02-24 20:02:15 2022-11-07 17:25:01 2022-02-24 16:58:02 2021-02-23 20:20:13
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 21M 44M 110M 11M 17M 13M 175M 59M 46M 19M 165M 27M 275M 123M
costOfRevenue 0 3M 0 0 3M 3M 0 3M 3M 0 0 0 0 170M
grossProfit 21M 41M 110M 11M 14M 10M 175M 56M 43M 19M 165M 27M 275M -47M
grossProfitRatio 1 0.939 1 0.822 0.763 0.947 0.937 1 1
researchAndDevelopmentExpenses 54M 62M 228M 58M 62M 57M 254M 65M 60M 64M 200M 53M 193M 170M
generalAndAdministrativeExpenses 14M 15M 61M 15M 18M 14M 53M 12M 11M 14M 47M 12M 39M 30M
sellingAndMarketingExpenses 0 0 0 0 -3M -3M 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 14M 15M 61M 15M 15M 11M 53M 12M 11M 14M 47M 12M 39M 30M
otherExpenses 0 -3M 0 0 -4000 0 0 -6M 4M -1M 0 0 0 -170M
operatingExpenses 69M 74M 289M 73M 76M 68M 307M 77M 72M 78M 247M 66M 231M 30M
costAndExpenses 69M 77M 289M 73M 79M 71M 307M 77M 72M 78M 247M 66M 231M 199M
interestIncome 7M 7M 32M 8M 8M 7M 19M 5M 4M 3M 5M 1M 862 000 7M
interestExpense 8M 8M 37M 795 000 844 000 0 0 0 0 -847 000 0 1M 13 000 0
depreciationAndAmortization 3M 3M 12M 3M 3M 3M 11M 3M 3M 2M 9M -3M 7M 6M
ebitda 4M -20M -186M -42M -63M -55M -102M -18M -26M -59M -46M -41M 90M -71M
ebitdaratio 0.201 -0.463 -3.963 -3.496 -4.281 -0.309 -0.571 -3.131 -1.517
operatingIncome -48M -33M -178M -62M -62M -58M -132M -18M -26M -59M -82M -38M 44M -77M
operatingIncomeRatio -2.263 -0.761 -5.815 -3.674 -4.518 -0.309 -0.571 -3.131 -1.405
totalOtherIncomeExpensesNet 41M 2M -57M 16M -5M -11M 13M -6M 4M -1M 28M 7M 39M 7M
incomeBeforeTax -6M -31M -235M -46M -67M -69M -120M -24M -22M -61M -55M -32M 83M -69M
incomeBeforeTaxRatio -0.287 -0.713 -4.323 -3.968 -5.366 -0.41 -0.482 -3.204 -1.16
incomeTaxExpense 0 -250 000 2M -1M 117 000 -676 000 14M -3M -3M -847 000 673 000 1M 0 0
netIncome -6M -31M -233M -45M -66M -68M -133M -24M -22M -60M -55M -33M 83M -69M
netIncomeRatio -0.287 -0.707 -4.215 -3.889 -5.313 -0.41 -0.482 -3.16 -1.2
eps -0.08 -0.41 -3.58 -0.71 -1.07 -1.11 -2.08 -0.4 -0.37 -1 -0.93 -0.55 1.42 -1.11
epsdiluted -0.08 -0.41 -0.71 -1.07 -1.11 -0.4 -0.37 -1 -0.55
weightedAverageShsOut 74M 74M 65M 64M 62M 61M 61M 61M 60M 60M 60M 60M 58M 57M
weightedAverageShsOutDil 74M 74M 65M 64M 62M 61M 61M 61M 60M 60M 60M 60M 60M 57M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2025-02-24 2023-02-27 2022-02-24 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -5M 19M 5M 849 000 7M
ebit -198M -113M -54M 83M -77M
nonOperatingIncomeExcludingInterest 20M -19M -28M -39M 0
netIncomeFromContinuingOperations -237M -133M -55M 83M -69M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -233M -133M -55M 83M -69M
epsDiluted -3.58 -2.08 -0.93 1.37 -1.11

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol XNCR XNCR XNCR XNCR XNCR XNCR XNCR XNCR XNCR XNCR XNCR XNCR XNCR XNCR
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-05 2025-08-06 2024-11-06 2024-08-05 2024-05-09 2023-11-08 2023-08-03 2023-05-08 2022-11-07
acceptedDate 2025-11-05 16:03:34 2025-08-06 16:02:58 2025-02-27 08:05:38 2024-11-06 16:09:09 2024-08-05 16:12:39 2024-05-09 16:02:08 2025-02-24 08:02:42 2023-11-07 18:00:25 2023-08-03 17:28:45 2023-05-08 17:15:39 2023-02-24 20:02:15 2022-11-07 17:25:01 2022-02-24 16:58:02 2021-02-23 20:20:13
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 28M 44M 41M 29M 31M 31M 54M 53M 35M 72M 54M 53M 143M 164M
shortTermInvestments 443M 399M 457M 435M 478M 505M 540M 442M 517M 516M 569M 548M 191M 439M
cashAndShortTermInvestments 471M 444M 498M 464M 508M 536M 594M 495M 551M 588M 623M 600M 334M 603M
netReceivables 22M 48M 61M 10M 22M 10M 11M 55M 20M 20M 29M 45M 66M 24M
inventory 0 0 0 0 0 1 0 0 1 0 0 0 0 0
otherCurrentAssets 26M 22M 19M 99M 24M 17M 18M 22M 22M 22M 23M 23M 0 0
totalCurrentAssets 518M 513M 578M 573M 554M 562M 623M 571M 594M 630M 675M 668M 424M 638M
propertyPlantEquipmentNet 93M 94M 98M 101M 103M 104M 100M 103M 101M 100M 94M 71M 60M 32M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 9M 11M 18M 18M 19M 19M 19M 19M 19M 18M 19M 0 16M 16M
goodwillAndIntangibleAssets 9M 11M 18M 18M 19M 19M 19M 19M 19M 18M 19M 18M 16M 16M
longTermInvestments 247M 260M 257M 290M 149M 199M 210M 85M 64M 54M 58M 73M 332M 17M
taxAssets 0 0 0 0 0 44M 0 0 0 0 0 0 5M 0
otherNonCurrentAssets 498 000 784 000 885 000 883 000 498 000 -43M 1M 660 000 598 000 599 000 613 000 6M 653 000 212 000
totalNonCurrentAssets 350M 366M 374M 410M 272M 322M 330M 207M 185M 173M 171M 167M 414M 66M
otherAssets 0 0 0 0 0 0 0 378 000 0 0 0 0 0 0
totalAssets 869M 879M 952M 984M 826M 884M 953M 778M 778M 803M 846M 835M 838M 703M
accountPayables 9M 19M 17M 19M 16M 16M 14M 15M 14M 15M 10M 15M 14M 9M
shortTermDebt 49M 3M 48M 10M 8M 10M 6M 4M 4M 4M 0 21M 0 0
taxPayables 0 0 10M 0 0 6M 6M 0 0 0 0 388 000 0 0
deferredRevenue 0 0 0 38M 36M 34M 32M 9M 8M 30M 30M 35M 37M 93M
otherCurrentLiabilities 28M 74M 0 25M 20M 19M 0 24M 18M 15M 0 20M 0 0
totalCurrentLiabilities 86M 96M 87M 92M 80M 79M 85M 53M 45M 65M 64M 90M 71M 121M
longTermDebt 153M 65M 115M 77M 79M 12M 15M 56M 55M 55M 0 23M 0 0
deferredRevenueNonCurrent 0 0 0 94M 104M 113M 125M 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 55M -180M 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 4M 98M 10M 0 0 247M 0 0 0 0 0 -48M 0 0
totalNonCurrentLiabilities 157M 163M 190M 171M 184M 193M 199M 56M 55M 55M 55M 23M 34M 10M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 65M 68M 68M 69M 68M 67M 62M 61M 59M 59M 60M 43M 34M 12M
totalLiabilities 243M 259M 278M 263M 264M 272M 284M 109M 99M 120M 119M 113M 105M 131M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 714 000 714 000 703 000 701 000 619 000 617 000 611 000 607 000 607 000 605 000 601 000 598 000 595 000 580 000
retainedEarnings -789M -783M -704M -644M -598M -532M -464M -445M -421M -399M -338M -326M -283M -366M
accumulatedOtherComprehensiveIncomeLoss 1M 258 000 -663 000 2M -652 000 -154 000 1M -709 000 -2M -4M -7M -10M -2M 74 000
othertotalStockholdersEquity 1 413M 1 403M 1 365M 1 163M 1 144M 1 114M 1 101M 1 086M 1 058M
totalStockholdersEquity 625M 620M 678M 724M 564M 613M 669M 669M 679M 684M 727M 723M 734M 572M
totalEquity 625M 620M 674M 721M 563M 612M 669M 669M 679M 684M 727M 723M 734M 572M
totalLiabilitiesAndStockholdersEquity 869M 879M 984M 826M 884M 778M 778M 803M 835M
minorityInterest 0 0 -4M -3M -2M -339 000 337 000 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 869M 879M 952M 984M 826M 884M 953M 778M 778M 803M 846M 835M 838M 703M
totalInvestments 690M 660M 714M 725M 627M 704M 750M 433M 541M 530M 627M 620M 522M 457M
totalDebt 202M 68M 232M 87M 88M 89M 83M 61M 59M 59M 60M 43M 34M 12M
netDebt 174M 23M 191M 58M 57M 58M 30M 8M 24M -13M 6M -10M -110M -152M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2025-02-24 2023-02-27 2022-02-24 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 61M 11M 29M 66M 11M
otherReceivables 0 0 0 0 13M
prepaids 0 0 0 24M 11M
totalPayables 17M 20M 10M 14M 9M
otherPayables 0 6M 0 0 0
accruedExpenses 19M 24M 19M 19M 18M
capitalLeaseObligationsCurrent 3M 3M 5M 0 2M
capitalLeaseObligationsNonCurrent 65M 59M 55M 34M 10M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 1 382M 1 131M 1 072M 1 018M 938M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol XNCR XNCR XNCR XNCR XNCR XNCR XNCR XNCR XNCR XNCR XNCR XNCR XNCR XNCR
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-05 2025-08-06 2024-11-06 2024-08-05 2024-05-09 2023-11-08 2023-08-03 2023-05-08 2022-11-07
acceptedDate 2025-11-05 16:03:34 2025-08-06 16:02:58 2025-02-27 08:05:38 2024-11-06 16:09:09 2024-08-05 16:12:39 2024-05-09 16:02:08 2025-02-24 08:02:42 2023-11-07 18:00:25 2023-08-03 17:28:45 2023-05-08 17:15:39 2023-02-24 20:02:15 2022-11-07 17:25:01 2022-02-24 16:58:02 2021-02-23 20:20:13
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -6M -31M -237M -48M -66M -68M -133M -24M -22M -61M -55M -33M 83M -69M
depreciationAndAmortization 3M 3M 12M 3M 3M 3M 11M 3M 3M 2M 9M 2M 7M 6M
deferredIncomeTax 0 0 0 0 0 0 0 0 0 0 0 0 -19M 0
stockBasedCompensation 10M 11M 53M 12M 17M 11M 0 13M 14M 13M 49M 13M 37M 32M
changeInWorkingCapital 20M -6M -40M 42M -27M -15M 19M -26M -20M 12M 49M 22M -103M 48M
accountsReceivables 20M -9M -33M 12M -12M 2M 20M -35M -157 000 9M 37M 9M -55M -185 000
inventory 0 0 0 0 0 0 0 6M 3M 0 0 0 1M 0
accountsPayables -9M 4M 3M 3M -173 000 2M 4M 870 000 -1M 5M -4M -1M 5M -1M
otherWorkingCapital 10M -2M -11M 27M -8M -19M -5M 2M -22M -2M 16M 13M -54M 50M
otherNonCashItems -58M -13M 9M -35M 43M 27M 25M 7M -13M 3M -27M -5M -22M -21M
netCashProvidedByOperatingActivities -31M -36M -202M -26M -65M -55M -78M -27M -38M -31M 24M -1M -17M -5M
investmentsInPropertyPlantAndEquipment -183 000 -383 000 -6M 274 000 -4M -1M -21M -3M -5M -11M -38M -15M -16M -11M
acquisitionsNet 0 0 0 0 0 0 501 000 587 000 1M 407 000 0 0 -3M 0
purchasesOfInvestments -84M -73M -595M -282M -123M -137M -783M -168M -181M -95M -388M -111M -510M -644M
salesMaturitiesOfInvestments 99M 108M 597M 114M 192M 170M 693M 217M 185M 155M 307M 129M 485M 758M
otherInvestingActivites 0 5M 4M 69M 32M -587 000 -1M -407 000 0
netCashUsedForInvestingActivites 15M 40M -163M 66M 32M 45M -1M 48M 3M
debtRepayment 0 0 0 0 -2M 0 0 0 0
commonStockIssued 0 662 000 198M 1M 2M 356 000 2M 922 000 0
commonStockRepurchased 0 0 0 930 000 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 0 188M -943 000 -2M 356 000 0 0 1M
netCashUsedProvidedByFinancingActivities 0 662 000 188M -943 000 186 000 356 000 2M 922 000 1M
effectOfForexChangesOnCash 0 -2000 0 0 0 0 -380 000 0 0 0 0 0 0 0
netChangeInCash -16M 5M -13M -1M -266 000 -23M -152 000 18M -38M 18M -90M 3M -20M 113M
cashAtEndOfPeriod 29M 45M 41M 29M 31M 31M 54M 53M 35M 72M 54M 53M 143M 164M
cashAtBeginningOfPeriod 45M 40M 54M 31M 31M 54M 54M 35M 72M 54M 143M 49M 164M 50M
operatingCashFlow -31M -36M -202M -26M -65M -55M -78M -27M -38M -31M 24M -1M -17M -5M
capitalExpenditure -183 000 -383 000 -6M 274 000 -4M -1M -18M -3M -5M -11M -43M -15M -16M -14M
freeCashFlow -31M -37M -208M -26M -69M -56M -96M -31M -43M -42M -19M -16M -33M -19M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2025-02-24 2023-02-27 2022-02-24 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -3M 0 90 000 -3M -3M
netCashProvidedByInvestingActivities -8M -111M -120M -46M 100M
netDebtIssuance 0 0 0 0 0
longTermNetDebtIssuance 0 0 0 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 201M 5M 0 29M 0
netCommonStockIssuance 201M 5M 0 29M 0
commonStockIssuance 201M 5M 0 29M 0
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -4M 183M 6M 14M 18M
netCashProvidedByFinancingActivities 197M 189M 6M 43M 18M
incomeTaxesPaid 6M 0 700 000 0 0
interestPaid 33 000 0 13 000 0 15 000

Earning call transcript

2023 q4
2024-02-28 ET (fiscal 2023 q4)
2023 q3
2023-11-08 ET (fiscal 2023 q3)
2023 q2
2023-08-06 ET (fiscal 2023 q2)
2023 q1
2023-05-08 ET (fiscal 2023 q1)
2022 q4
2023-02-23 ET (fiscal 2022 q4)
2022 q3
2022-11-07 ET (fiscal 2022 q3)
2022 q2
2022-08-03 ET (fiscal 2022 q2)
2022 q1
2022-05-08 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-01-08 ET
Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones
2025-12-09 ET
Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies
2025-11-10 ET
Xencor to Participate at Upcoming Investor Conferences
2025-11-05 ET
Xencor Reports Third Quarter 2025 Financial Results
2025-10-24 ET
Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma
2025-10-21 ET
Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
2025-10-17 ET
Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation
2025-10-14 ET
Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
2025-08-27 ET
Xencor to Participate at Upcoming Investor Conferences
2025-07-31 ET
Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors
2025-05-07 ET
Xencor Reports First Quarter 2025 Financial Results
2025-04-29 ET
Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease
2025-03-13 ET
Xencor Appoints Todd Simpson to Board of Directors
2025-02-27 ET
Xencor Reports Fourth Quarter and Full Year 2024 Financial Results
2024-11-26 ET
Xencor to Participate at Upcoming Investor Conferences
2024-11-06 21:01 ET
Xencor Reports Third Quarter 2024 Financial Results
2024-11-04 12:00 ET
Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease
2024-10-10 12:09 ET
Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases
2024-10-04 12:01 ET
Xencor Announces Upcoming Change to Board of Directors
2024-09-12 20:01 ET
Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
2024-09-11 10:31 ET
Xencor Announces Pricing of $175 Million Public Offering of Common Stock
2024-09-10 20:01 ET
Xencor Announces Proposed Public Offering of Common Stock
2024-09-09 11:31 ET
Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs
2024-09-06 12:01 ET
Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024
2024-08-05 20:01 ET
Xencor Reports Second Quarter 2024 Financial Results
2024-06-13 12:01 ET
Xencor Regains CD20 x CD3 Bispecific T-Cell Engager
2024-05-09 20:09 ET
Xencor Reports First Quarter 2024 Financial Results
2024-04-09 12:01 ET
Xencor Appoints Bart Cornelissen as Chief Financial Officer
2024-02-28 21:01 ET
Xencor to Present at Upcoming Investor Conferences
2024-02-27 21:01 ET
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-20 21:31 ET
Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update
2024-01-03 21:01 ET
Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2024-01-02 13:01 ET
Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy
2023-11-21 21:01 ET
Xencor to Present at the Piper Sandler 35th Annual Healthcare Conference
2023-11-07 21:01 ET
Xencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 Million
2023-11-07 21:01 ET
Xencor Reports Third Quarter 2023 Financial Results
2023-11-03 16:01 ET
Xencor Presents Preclinical Data from Multiple XmAb® Research Programs at the SITC Annual Meeting
2023-10-31 20:01 ET
Xencor to Host Third Quarter 2023 Financial Results Webcast and Conference Call on November 7, 2023
2023-10-26 12:01 ET
Xencor Announces Planned Retirement of Chief Financial Officer John Kuch
2023-09-27 13:01 ET
Xencor to Present Multiple Posters at the SITC Annual Meeting
2023-09-19 20:01 ET
Xencor Appoints Barbara J. Klencke, M.D., to Board of Directors
2023-08-03 20:01 ET
Xencor Reports Second Quarter 2023 Financial Results
2023-07-27 12:01 ET
Xencor to Host Second Quarter 2023 Financial Results Webcast and Conference Call on August 3, 2023
2023-05-30 22:01 ET
Xencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress
2023-05-08 20:01 ET
Xencor Reports First Quarter 2023 Financial Results
2023-05-01 20:01 ET
Xencor to Host First Quarter 2023 Financial Results Webcast and Conference Call on May 8, 2023
2023-04-26 12:01 ET
Xencor Appoints Nancy Valente, M.D., as Chief Development Officer
2023-04-17 17:31 ET
Xencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023
2023-03-14 20:31 ET
Xencor to Present Preclinical Data from Novel XmAb® CD28 Bispecific Antibody Programs at the American Association for Cancer Research Annual Meeting 2023
2023-02-23 21:01 ET
Xencor Reports Fourth Quarter and Full Year 2022 Financial Results
2023-02-16 21:01 ET
Xencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023
2023-02-07 21:01 ET
Xencor to Present at the SVB Securities Global Biopharma Conference
2023-01-09 13:01 ET
Xencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates
2023-01-05 11:30 ET
Caris Life Sciences and Xencor Expand Target Discovery Collaboration for Novel XmAb® Antibody Drug Candidates
2023-01-04 21:01 ET
Xencor to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-12 15:00 ET
Xencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual Meeting
2022-11-10 21:01 ET
Xencor to Present at Upcoming Investor Conferences
2022-11-10 14:01 ET
Xencor Presents Early Clinical Data from Combination Study of Vudalimab and New Data from Multiple Preclinical-stage XmAb® Programs at the SITC Annual Meeting
2022-11-07 21:01 ET
Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study
2022-11-07 21:01 ET
Xencor Reports Third Quarter 2022 Financial Results
2022-11-03 13:01 ET
Xencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin’s Lymphoma at the American Society of Hematology Annual Meeting
2022-10-31 20:01 ET
Xencor to Host Third Quarter 2022 Financial Results Webcast and Conference Call on November 7, 2022
2022-10-05 12:01 ET
Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting
2022-09-09 12:01 ET
Xencor Appoints Nancy Valente, M.D., to Board of Directors
2022-08-03 20:01 ET
Xencor Reports Second Quarter 2022 Financial Results
2022-08-02 10:30 ET
Caris Life Sciences and Xencor Enter Target Discovery Collaboration and License Agreement for Novel XmAb® Bispecific Antibodies
2022-07-27 20:01 ET
Xencor to Host Second Quarter 2022 Financial Results Webcast and Conference Call on August 3, 2022
2022-05-26 21:01 ET
Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors
2022-05-05 20:01 ET
Xencor Reports First Quarter 2022 Financial Results
2022-04-28 20:01 ET
Xencor to Host First Quarter 2022 Financial Results Webcast and Conference Call on May 5, 2022
2022-04-08 17:01 ET
Xencor Presents Data from Multiple Preclinical XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022
2022-03-08 21:31 ET
Xencor to Present Preclinical Data from XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022
2022-02-23 21:01 ET
Xencor Reports Fourth Quarter and Full Year 2021 Financial Results
2022-02-16 21:01 ET
Xencor to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 23, 2022
2022-02-02 21:01 ET
Xencor to Present at Upcoming Investor Conferences
2022-01-11 13:01 ET
Xencor Highlights 2022 Corporate Priorities and Portfolio Milestones
2022-01-06 21:01 ET
Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference
2021-12-12 12:00 ET
Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting
2021-11-21 23:00 ET
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor
2021-11-21 23:00 ET
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor
2021-11-19 21:01 ET
Xencor to Present at Upcoming Investor Conferences
2021-11-12 12:00 ET
Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the SITC Annual Meeting
2021-11-12 12:00 ET
Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting
2021-11-08 21:01 ET
Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306
2021-11-04 13:00 ET
Xencor to Present Data from the Phase 1 Study of Plamotamab in B-Cell Malignancies at the American Society of Hematology Annual Meeting
2021-11-03 13:00 ET
Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium
2021-11-02 20:01 ET
Xencor to Present at Upcoming Investor Conferences
2021-11-01 20:01 ET
Xencor to Host Third Quarter 2021 Financial Results Webcast and Conference Call on November 8, 2021
2021-10-04 11:00 ET
Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients With B-Cell Malignancies
2021-10-01 12:01 ET
Xencor to Present Data from the Phase 1 Study of Vudalimab (XmAb®717) and Four Research Programs at the SITC Annual Meeting
2021-09-20 20:01 ET
Xencor to Present at the 2021 Cantor Virtual Global Healthcare Conference
2021-08-04 20:01 ET
Xencor Reports Second Quarter 2021 Financial Results
2021-08-02 20:01 ET
Xencor to Present at Upcoming Investor Conferences
2021-07-28 20:01 ET
Xencor to Host Second Quarter 2021 Financial Results Webcast and Conference Call on August 4, 2021
2021-05-27 20:01 ET
Xencor to Present at the Jefferies Virtual Healthcare Conference
2021-05-26 23:46 ET
Sotrovimab (VIR-7831), an Investigational Antibody Utilizing Xencor's Xtend™ Technology, Receives U.S. FDA Emergency Use Authorization for the Treatment of COVID-19
2021-05-25 12:01 ET
Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend™ XmAb® Technology in SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
2021-05-12 20:01 ET
Xencor to Present at the 2021 RBC Capital Markets Global Healthcare Virtual Conference
2021-05-05 20:01 ET
Xencor Reports First Quarter 2021 Financial Results
2021-04-28 20:01 ET
Xencor Doses First Subject in Phase 1 Study of XmAb®564, an Engineered IL-2 Cytokine in Development for Autoimmune Diseases
2021-04-28 20:00 ET
Xencor to Host First Quarter 2021 Financial Results Webcast and Conference Call on May 5, 2021
2021-04-10 12:30 ET
Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the AACR Annual Meeting 2021
2021-03-11 01:15 ET
Xencor to Present Preclinical Data from Four Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2021
2021-03-03 21:01 ET
Xencor to Present at the Barclays Global Healthcare Conference
2021-02-25 10:01 ET
Xencor and UCLA Enter Collaboration to Discover and Develop Novel XmAb® Therapeutics
2021-02-23 21:01 ET
Xencor Reports Fourth Quarter and Full Year 2020 Financial Results
2021-02-16 21:01 ET
Xencor to Host Fourth Quarter and Full Year 2020 Financial Results Webcast and Conference Call on February 23, 2021
2021-02-04 21:01 ET
Xencor to Present at Upcoming Investor Conferences
2021-01-06 21:01 ET
Xencor and MD Anderson Enter Strategic Collaboration to Develop Novel T Cell-Engaging Bispecific Antibodies for Potential Treatment of Patients with Cancer
2020-12-07 13:01 ET
Xencor Enters Collaboration with Janssen with Aim to Discover Novel CD28 Bispecific Antibodies for the Treatment of Prostate Cancer
2020-12-06 22:00 ET
Xencor Presents Updated Data from the Phase 1 Study of Vibecotamab in Acute Myeloid Leukemia at the 2020 ASH Annual Meeting
2020-11-12 21:01 ET
Xencor to Present at Upcoming Investor Conferences
2020-11-09 13:00 ET
Xencor Presents Updated Data From the DUET-2 Phase 1 Study of XmAb20717, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting
2020-11-09 13:00 ET
Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the SITC Annual Meeting
2020-11-05 21:01 ET
Xencor Reports Third Quarter 2020 Financial Results
2020-11-04 15:15 ET
Xencor to Present Data from Phase 1 Study of Vibecotamab in Acute Myeloid Leukemia at the 2020 ASH Annual Meeting
2020-10-29 20:01 ET
Xencor to Host Third Quarter 2020 Financial Results Webcast and Conference Call on November 5, 2020
2020-10-14 21:00 ET
Xencor to Present Data from the Phase 1 Study of XmAb®20717 and Three Research Programs at the SITC Annual Meeting
2020-10-02 13:00 ET
Xencor Presents Initial Data From the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium
2020-09-09 20:01 ET
Xencor to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference
2020-09-09 12:01 ET
Xencor to Present Initial Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium
2020-09-03 12:01 ET
Xencor and MD Anderson Enter Strategic Collaboration to Advance Investigational XmAb® Drug Candidates
2020-08-05 20:01 ET
Xencor to Present at Upcoming Investor Conferences
2020-08-04 20:01 ET
Xencor Reports Second Quarter 2020 Financial Results
2020-08-01 02:49 ET
Xencor Earns Milestone Payment from MorphoSys for FDA Approval of Monjuvi® (tafasitamab-cxix) in the United States
2020-07-28 21:01 ET
Xencor to Host Second Quarter 2020 Financial Results Webcast and Conference Call on August 4, 2020
2020-07-08 12:01 ET
Xencor and Atreca Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies
2020-07-08 12:01 ET
Atreca and Xencor Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies
2020-06-22 13:06 ET
Xencor Presents Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II
2020-05-26 20:01 ET
Xencor to Present at Upcoming Investor Conferences
2020-05-15 04:01 ET
Xencor to Present Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II
2020-05-13 21:00 ET
Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®20717, PD-1 x CTLA-4 Bispecific Antibody, in Solid Tumors
2020-05-13 13:01 ET
Xencor to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference
2020-05-07 20:01 ET
Xencor Reports First Quarter 2020 Financial Results
2020-04-30 20:01 ET
Xencor to Host First Quarter 2020 Financial Results Webcast and Conference Call on May 7, 2020
2020-03-25 20:01 ET
Xencor and Vir Biotechnology Enter License Agreement for Use of Xtend™ XmAb® Antibody Technology in Investigational Antibodies to Treat COVID-19
2020-02-24 21:01 ET
Xencor Reports Fourth Quarter and Full Year 2019 Financial Results
2020-02-18 13:01 ET
Xencor to Host Fourth Quarter and Full Year 2019 Financial Results Webcast and Conference Call on February 24, 2020
2020-02-06 21:01 ET
Xencor to Present at Upcoming Investor Conferences
2020-02-05 13:01 ET
Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development of Next-Generation Food Allergy Treatments
2020-01-08 13:01 ET
Xencor and Gilead Enter License Agreement for Use of XmAb® Antibody Technologies in Investigational Agents for HIV
2019-12-20 13:01 ET
Xencor Appoints Dagmar Rosa-Bjorkeson to Board of Directors
2019-12-18 13:01 ET
Xencor Appoints Allen Yang, M.D., Ph.D., as Senior Vice President and Chief Medical Officer
2019-12-09 15:00 ET
Xencor Presents Initial Data from Phase 1 Study of XmAb®13676 in B-cell Malignancies at the ASH Annual Meeting
2019-11-06 14:00 ET
Xencor to Present Initial Data from the Phase 1 Study of XmAb®13676 in B-Cell Malignancies at the American Society of Hematology Annual Meeting
2019-11-05 21:01 ET
Xencor Reports Third Quarter 2019 Financial Results
2019-10-29 20:01 ET
Xencor to Host Third Quarter 2019 Financial Results Webcast and Conference Call on November 5, 2019
2019-09-26 20:01 ET
Xencor to Present at the 2019 Cantor Global Healthcare Conference
2019-09-10 20:01 ET
Xencor Appoints Celia Eckert as Vice President, General Counsel and Corporate Secretary

SEC forms

Show financial reports only

SEC form 8
2026-01-08 13:05 ET
Xencor published news for 2025 q4
SEC form 8
2026-01-08 13:05 ET
Xencor published news for 2025 q4
SEC form 10
2025-11-05 21:03 ET
Xencor reported for 2025 q3
SEC form 8
2025-11-05 21:02 ET
Xencor published news for 2025 q3
SEC form 8
2025-11-05 21:02 ET
Xencor reported for 2025 q3
SEC form 8
2025-10-24 17:57 ET
Xencor published news for 2025 q3
SEC form 8
2025-10-24 17:57 ET
Xencor published news for 2025 q3
SEC form 8
2025-10-24 17:57 ET
Xencor published news for 2025 q3
SEC form 10
2025-08-06 20:02 ET
Xencor reported for 2025 q2
SEC form 8
2025-08-06 20:01 ET
Xencor published news for 2025 q2
SEC form 8
2025-08-06 20:01 ET
Xencor reported for 2025 q2
SEC form 10
2025-05-07 20:09 ET
Xencor published news for 2025 q1
SEC form 8
2025-05-07 20:03 ET
Xencor published news for 2025 q1
SEC form 8
2025-05-07 20:03 ET
Xencor reported for 2025 q1
SEC form 10
2025-05-07 00:00 ET
Xencor published news for 2025 q1
SEC form 8
2025-04-29 22:01 ET
Xencor published news for 2025 q1
SEC form 8
2025-04-29 22:01 ET
Xencor published news for 2025 q1
SEC form 8
2025-04-29 22:01 ET
Xencor published news for 2025 q1
SEC form 8
2025-03-13 20:42 ET
Xencor published news for 2024 q4
SEC form 8
2025-03-13 20:42 ET
Xencor published news for 2024 q4
SEC form 10
2025-02-27 13:05 ET
Xencor published news for 2024 q4
SEC form 10
2025-02-27 00:00 ET
Xencor published news for 2024 q4
SEC form 8
2025-02-27 00:00 ET
Xencor published news for 2024 q4
SEC form 8
2025-02-27 00:00 ET
Xencor reported for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Xencor published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Xencor published news for 2024 q4
SEC form 10
2024-11-06 16:09 ET
Xencor published news for 2024 q3
SEC form 8
2024-11-06 16:03 ET
Xencor published news for 2024 q3
SEC form 8
2024-11-06 16:03 ET
Xencor reported for 2024 q3
SEC form 10
2024-08-05 16:12 ET
Xencor published news for 2024 q2
SEC form 8
2024-08-05 16:06 ET
Xencor published news for 2024 q2
SEC form 8
2024-08-05 16:06 ET
Xencor reported for 2024 q2
SEC form 10
2024-08-05 00:00 ET
Xencor published news for 2024 q2
SEC form 10
2024-05-09 00:00 ET
Xencor published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Xencor published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Xencor reported for 2024 q1
SEC form 10
2024-02-29 00:00 ET
Xencor published news for 2023 q4
SEC form 8
2024-02-27 16:05 ET
Xencor published news for 2023 q4
SEC form 8
2024-02-27 16:05 ET
Xencor reported for 2023 q4
SEC form 10
2023-11-08 00:00 ET
Xencor published news for 2023 q3
SEC form 10
2023-11-07 18:00 ET
Xencor published news for 2023 q3
SEC form 8
2023-11-07 16:04 ET
Xencor reported for 2023 q3
SEC form 10
2023-08-03 17:28 ET
Xencor reported for 2023 q2
SEC form 6
2023-08-03 16:02 ET
Xencor reported for 2023 q2
SEC form 10
2023-08-03 00:00 ET
Xencor published news for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Xencor published news for 2023 q2
SEC form 6
2023-07-03 07:16 ET
Xencor published news for 2023 q2
SEC form 6
2023-06-14 17:55 ET
Xencor published news for 2023 q1
SEC form 10
2023-05-08 00:00 ET
Xencor published news for 2023 q1
SEC form 8
2023-05-08 00:00 ET
Xencor published news for 2023 q1
SEC form 6
2023-03-10 21:37 ET
Xencor published news for 2022 q4
SEC form 6
2023-02-28 16:40 ET
Xencor published news for 2022 q4
SEC form 10
2023-02-27 00:00 ET
Xencor reported for 2022 q4
SEC form 10
2023-02-24 20:02 ET
Xencor reported for 2022 q4
SEC form 6
2023-02-23 16:27 ET
Xencor published news for 2022 q4
SEC form 8
2023-02-23 00:00 ET
Xencor reported for 2022 q4
SEC form 10
2022-11-07 17:25 ET
Xencor reported for 2022 q3
SEC form 6
2022-11-07 16:31 ET
Xencor published news for 2022 q3
SEC form 10
2022-11-07 00:00 ET
Xencor reported for 2022 q3
SEC form 8
2022-11-07 00:00 ET
Xencor reported for 2022 q3
SEC form 6
2022-09-09 08:05 ET
Xencor published news for 2022 q2
SEC form 10
2022-08-03 16:54 ET
Xencor reported for 2022 q2
SEC form 6
2022-08-03 16:12 ET
Xencor published news for 2022 q2
SEC form 10
2022-08-03 00:00 ET
Xencor reported for 2022 q2
SEC form 8
2022-08-03 00:00 ET
Xencor reported for 2022 q2
SEC form 6
2022-06-28 17:00 ET
Xencor published news for 2022 q1
SEC form 10
2022-05-05 17:01 ET
Xencor reported for 2022 q1
SEC form 6
2022-05-05 16:01 ET
Xencor published news for 2022 q1
SEC form 10
2022-05-05 00:00 ET
Xencor reported for 2022 q1
SEC form 8
2022-05-05 00:00 ET
Xencor reported for 2022 q1
SEC form 6
2022-04-27 16:06 ET
Xencor published news for 2022 q1
SEC form 10
2022-02-24 16:58 ET
Xencor published news for 2021 q4
SEC form 10
2022-02-24 00:00 ET
Xencor published news for 2021 q4
SEC form 6
2022-02-23 16:02 ET
Xencor published news for 2021 q4
SEC form 8
2022-02-23 00:00 ET
Xencor published news for 2021 q4
SEC form 10
2021-11-08 17:19 ET
Xencor published news for 2021 q3
SEC form 6
2021-11-08 16:01 ET
Xencor published news for 2021 q3
SEC form 10
2021-11-08 00:00 ET
Xencor published news for 2021 q3
SEC form 8
2021-11-08 00:00 ET
Xencor published news for 2021 q3
SEC form 6
2021-10-04 13:14 ET
Xencor published news for 2021 q3
SEC form 10
2021-08-04 17:23 ET
Xencor published news for 2021 q2
SEC form 6
2021-08-04 16:04 ET
Xencor published news for 2021 q2
SEC form 10
2021-08-04 00:00 ET
Xencor published news for 2021 q2
SEC form 8
2021-08-04 00:00 ET
Xencor published news for 2021 q2
SEC form 6
2021-07-06 16:30 ET
Xencor published news for 2021 q2
SEC form 6
2021-06-28 16:31 ET
Xencor published news for 2021 q1
SEC form 10
2021-05-05 17:26 ET
Xencor published news for 2021 q1
SEC form 6
2021-05-05 16:02 ET
Xencor published news for 2021 q1
SEC form 10
2021-05-05 00:00 ET
Xencor published news for 2021 q1
SEC form 8
2021-05-05 00:00 ET
Xencor published news for 2021 q1
SEC form 6
2021-04-28 16:12 ET
Xencor published news for 2021 q1
SEC form 6
2021-03-10 20:00 ET
Xencor published news for 2020 q4
SEC form 6
2021-03-10 20:00 ET
Xencor published news for 2020 q4
SEC form 6
2021-03-10 16:24 ET
Xencor published news for 2020 q4
SEC form 6
2021-03-03 20:00 ET
Xencor published news for 2020 q4
SEC form 6
2021-03-03 20:00 ET
Xencor published news for 2020 q4
SEC form 6
2021-03-03 20:00 ET
Xencor published news for 2020 q4
SEC form 10
2021-02-23 20:20 ET
Xencor published news for 2020 q4
SEC form 6
2021-02-23 16:01 ET
Xencor published news for 2020 q4
SEC form 6
2020-12-07 11:18 ET
Xencor published news for 2020 q3
SEC form 6
2020-11-30 17:07 ET
Xencor published news for 2020 q3
SEC form 10
2020-11-05 18:44 ET
Xencor published news for 2020 q3
SEC form 6
2020-11-05 16:01 ET
Xencor published news for 2020 q3
SEC form 6
2020-10-14 17:19 ET
Xencor published news for 2020 q3